VUITY
Drug
AbbVie Inc.
Total Payments
$6.5M
Transactions
44,500
Doctors
17,031
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2,683 | 5 | 5 |
| 2023 | $1.3M | 6,025 | 3,416 |
| 2022 | $5.1M | 36,899 | 15,643 |
| 2021 | $92,049 | 1,571 | 1,380 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,442 | 49.4% |
| Food and Beverage | $1.5M | 40,061 | 22.5% |
| Consulting Fee | $849,510 | 761 | 13.1% |
| Travel and Lodging | $510,683 | 2,105 | 7.9% |
| Unspecified | $431,576 | 86 | 6.7% |
| Grant | $30,666 | 13 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $2,900 | 2 | 0.0% |
| Education | $219.23 | 30 | 0.0% |
Payments by Type
General
$6.0M
44,414 transactions
Research
$431,576
86 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia | ABBVIE INC. | $244,173 | 0 |
| Presbyopia correcting drops in combination with multifocal and EDOF IOLs | ABBVIE INC. | $126,374 | 0 |
| Improved near vision and intermediate without loss of binocular distance vision using AGN190584 in subjects utilizing single contact lenses for distance vision correction both eyes | ABBVIE INC. | $47,653 | 0 |
| Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). | ABBVIE INC. | $12,657 | 0 |
| A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) | ABBVIE INC. | $719.06 | 0 |
Top Doctors Receiving Payments for VUITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Gregory Manion | — | Anacortes, WA | $453,317 | 124 |
| , M.D | Specialist | Baltimore, MD | $270,503 | 348 |
| , O.D | Optometrist | Edmond, OK | $196,758 | 274 |
| , M.D | Ophthalmology | Eatontown, NJ | $129,269 | 186 |
| , O.D | Optometrist | Bowling Green, OH | $127,518 | 129 |
| , OD | Corneal and Contact Management | Phoenix, AZ | $121,129 | 205 |
| , O.D., M.P.H | Optometrist | Hazle Township, PA | $112,089 | 118 |
| , MD | Specialist | Sun City West, AZ | $107,529 | 143 |
| , O.D | Optometrist | Tulsa, OK | $100,783 | 192 |
| , MD | Ophthalmology | Greensboro, NC | $100,588 | 119 |
| , OD | Optometrist | Memphis, TN | $99,461 | 177 |
| , MD | Cornea and External Diseases Specialist | Seattle, WA | $98,168 | 116 |
| , M.D | Ophthalmology | Woodland Park, NJ | $87,071 | 92 |
| , M.D | Ophthalmology | New York, NY | $84,493 | 65 |
| , OD | Optometrist | Pittsburg, KS | $83,589 | 160 |
| , MD | Ophthalmology | Des Plaines, IL | $83,289 | 66 |
| , O.D | Optometrist | Chicago, IL | $78,532 | 109 |
| , M.D | Ophthalmology | Bradenton, FL | $70,789 | 57 |
| , OD | Optometrist | Atlanta, GA | $60,728 | 112 |
| , O.D | Optometrist | Sioux Falls, SD | $55,182 | 76 |
| , MD | Ophthalmology | Petaluma, CA | $54,453 | 72 |
| , OD | Optometrist | Houston, TX | $51,785 | 138 |
| , OD | Optometrist | Raleigh, NC | $51,720 | 49 |
| , MD | Ophthalmology | Rock Island, IL | $51,262 | 53 |
| , O.D | Optometrist | Gonzales, LA | $50,755 | 73 |
Ad
Manufacturing Companies
- ABBVIE INC. $3.0M
- Allergan, Inc. $2.8M
- AbbVie Inc. $637,249
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 17,031
- Transactions 44,500
About VUITY
VUITY is a drug associated with $6.5M in payments to 17,031 healthcare providers, recorded across 44,500 transactions in the CMS Open Payments database. The primary manufacturer is AbbVie Inc..
Payment data is available from 2021 to 2024. In 2024, $2,683 was paid across 5 transactions to 5 doctors.
The most common payment nature for VUITY is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.2M, 49.4% of total).
VUITY is associated with 5 research studies, including "Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia" ($244,173).